Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Matt Abernethy sold 1,645 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $116.33, for a total transaction of $191,362.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of NBIX traded up $0.93 during mid-day trading on Wednesday, reaching $118.57. The stock had a trading volume of 760,352 shares, compared to its average volume of 827,848. The firm has a market cap of $10.74 billion, a price-to-earnings ratio of 538.95, a PEG ratio of 5.90 and a beta of 1.24. Neurocrine Biosciences, Inc. has a 12 month low of $64.72 and a 12 month high of $119.65. The business has a fifty day moving average of $106.73 and a 200 day moving average of $94.00. The company has a debt-to-equity ratio of 0.83, a quick ratio of 6.99 and a current ratio of 7.08.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.63 by ($0.07). The firm had revenue of $222.09 million during the quarter, compared to the consensus estimate of $211.31 million. Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The business’s revenue for the quarter was up 46.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.52 earnings per share. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 0.82 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of NBIX. Capital Investment Advisory Services LLC bought a new position in shares of Neurocrine Biosciences in the second quarter worth approximately $43,000. NEXT Financial Group Inc boosted its position in shares of Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after purchasing an additional 265 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Neurocrine Biosciences by 70.5% in the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock worth $51,000 after purchasing an additional 246 shares during the period. Flagship Harbor Advisors LLC bought a new position in shares of Neurocrine Biosciences in the third quarter worth approximately $67,000. Finally, Golden State Wealth Management LLC boosted its position in shares of Neurocrine Biosciences by 100.0% in the second quarter. Golden State Wealth Management LLC now owns 1,000 shares of the company’s stock worth $84,000 after purchasing an additional 500 shares during the period. Institutional investors and hedge funds own 97.13% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Featured Story: Front-End Load
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.